Winvild-M Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues, thereby enhancing glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner, contributing to improved glycemic control. The synergistic action of these agents helps in achieving better control of fasting and postprandial blood glucose levels. Winvild-M is typically prescribed when diet, exercise, and monotherapy with either agent do not provide adequate glycemic control. It is important to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as headache and dizziness. Patients should be advised to adhere to prescribed dosages and report any adverse effects promptly. Winvild-M should be used as part of a comprehensive diabetes management plan including lifestyle modifications.